When is off-label off-road?
作者信息
de Vries E G E, Cherny N I, Voest E E
机构信息
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel.
出版信息
Ann Oncol. 2019 Oct 1;30(10):1536-1538. doi: 10.1093/annonc/mdz445.
Abstract
摘要
相似文献
1
When is off-label off-road?
Ann Oncol. 2019 Oct 1;30(10):1536-1538. doi: 10.1093/annonc/mdz445.
2
[Legal issues in the off-label use of drug medication in in pediatrics].
J Dtsch Dermatol Ges. 2006 May;4(5):421-6. doi: 10.1111/j.1610-0387.2006.05983.x.
3
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
Ann Oncol. 2019 Oct 1;30(10):1647-1652. doi: 10.1093/annonc/mdz232.
4
The strange allure of state "right-to-try" laws.
JAMA Intern Med. 2014 Dec;174(12):1885-6. doi: 10.1001/jamainternmed.2014.5767.
5
New FDA breakthrough-drug category--implications for patients.
N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493.
6
The need for a journal policy on intrathecal, epidural, and perineural administration of non-approved drugs.
Pain. 2010 Jun;149(3):417-419. doi: 10.1016/j.pain.2010.02.028. Epub 2010 Mar 15.
7
Off-label drug use in children should be rational.
Arch Dis Child. 2011 Sep;96(9):870-1. doi: 10.1136/archdischild-2011-300293. Epub 2011 Jun 28.
8
Free Speech and Pharmaceutical Regulation -- Fishy Business.
JAMA Intern Med. 2016 Mar;176(3):295-6. doi: 10.1001/jamainternmed.2015.8155.
9
Informed consent in off-label use and incapacitated persons.
Epilepsia. 2009 Dec;50 Suppl 12:79-80. doi: 10.1111/j.1528-1167.2009.02354.x.
10
ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.
J Med Toxicol. 2020 Jul;16(3):342-345. doi: 10.1007/s13181-020-00784-6. Epub 2020 Jun 4.
引用本文的文献
1
The Role of Algorithms in Molecular Tumour Boards-Managing the Gap Between Research and Clinic in Precision Medicine.
Sociol Health Illn. 2025 May;47(4):e70040. doi: 10.1111/1467-9566.70040.
2
Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.
J Clin Med. 2025 Mar 30;14(7):2376. doi: 10.3390/jcm14072376.
3
Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.
Cancer Med. 2023 Aug;12(16):17112-17125. doi: 10.1002/cam4.6360. Epub 2023 Jul 26.
4
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
ESMO Open. 2023 Feb;8(1):100604. doi: 10.1016/j.esmoop.2022.100604. Epub 2022 Nov 14.
5
How to read a next-generation sequencing report-what oncologists need to know.
ESMO Open. 2022 Oct;7(5):100570. doi: 10.1016/j.esmoop.2022.100570. Epub 2022 Sep 29.
6
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.
Cancers (Basel). 2022 Jun 29;14(13):3193. doi: 10.3390/cancers14133193.
本文引用的文献
1
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
Ann Oncol. 2019 Oct 1;30(10):1647-1652. doi: 10.1093/annonc/mdz232.
2
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119.
3
The promise of ESCAT: a new system for evaluating cancer drug-target pairs.
Nat Rev Clin Oncol. 2019 Mar;16(3):147-148. doi: 10.1038/s41571-018-0110-3.
4
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.
5
6
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.
7
Prevalence of off-label use of oral oncolytics at a community cancer center.
J Oncol Pract. 2015 Mar;11(2):e139-43. doi: 10.1200/JOP.2014.001354. Epub 2015 Jan 20.
8
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19.
Zotero 插件